摘要
为了评价重组人白介素 11治疗前期再生障碍性贫血的血小板减少的疗效 ,对 6例早期再生障碍性贫血患者用重组人白介素 116 0 0万单位皮下注射 ,每日 1次 ,疗程 7- 14天 ,并分别于治疗前、治疗后第 8天、第 15天、第 30天、第 6 0天复查外周血血小板 ,第 15天复查骨髓巨核细胞计数。结果表明 :显效 3例 (5 0 % ) ,良效 1例(16 .7% ) ,进步 1例 (16 .7% ) ,无效 1例 (16 .7% ) ,总有效率 83.3%。全部 6例病人骨髓巨核细胞均有不同程度增加 ,治疗时副作用轻。结论 :重组人白介素 11治疗前期再生障碍性贫血血小板减少的疗效满意。
To evaluate the clinical efficacy of recombinant human Interleukin 11 in the treatment of pre-aplastic anemia, six patients with pre-aplastic anemia were injected with rhIL-11 of 6 million units once a day during 7-14 days. Blood platelet counts were taken on day 8, 15, 30 and 60 after the treatment, and bone marrow examination was performed on day 15 as compared with those before treetment. The results showed that platelet counts in 3 out of 6 patients increased remarkably (50%), one of the six increased moderately (16.7%), another case of the six increased slightly (16.7%), platelet in one out of six did not significantly increase (16.7%), the total efficacy rate is 83.3%, the amount of megakaryocyte in bone marrow of all six patients increased, the side effect of the rhIL-11 treatment was light. In conclusion, the efficacy of recombinant human Interleukin-11 in the treatment of thrombocytopenia patients with pre-aplastic anemia is satistactory. As the number of the cases is too small to conclude, further exploration needs accumnlation of more applications.
出处
《中国实验血液学杂志》
CAS
CSCD
2005年第1期151-153,共3页
Journal of Experimental Hematology
